GX BP1
Alternative Names: EPDeg™-SOX2; GX-BP1; SOX2-bioPROTACLatest Information Update: 28 Jan 2026
At a glance
- Originator Genexine
- Class Antineoplastics; Single-domain antibodies
- Mechanism of Action SOXB1 transcription factor degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours; Squamous cell cancer
Most Recent Events
- 15 Dec 2025 Pharmacodynamics data from preclinical trials in Non-small cell lung cancer released by Genexine (Genexine pipeline, December 2025)
- 14 Dec 2025 Preclinical trials in Solid tumours (Combination therapy) in South Korea (IV), before December 2025 (Genexine pipeline, December 2025)
- 14 Dec 2025 Preclinical trials in Squamous cell cancer in South Korea (IV), before December 2025 (Genexine pipeline, December 2025)